



A34759 069906.0102

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant : Mitchell et al.

Serial. No. : 10/075,028 Examiner: Gibbs, Terra

Filed : February 12, 2002 Group Art Unit: 1635

For : METHODS AND COMPOSITIONS FOR USE IN  
SPLICOSOME MEDIATED RNA *TRANS*-SPLICING

E  
#12/K.T.  
4/29  
57/13

SUBMISSION OF SUBSTITUTE SEQUENCE LISTING

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: BOX SEQUENCE, U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202.

April 22, 2003  
Date of Deposit

Carmella L. Stephens  
Attorney Name

41,328

Carmella L. Stephen  
Signature

April 22, 2003  
Date of Signature

**BOX SEQUENCE**  
U.S. Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

Sir:

In response to the Office Communication mailed April 7, 2003, applicants submit herewith a substitute Sequence Listing in computer and paper form, in accordance with 37 C.F.R. §1.821-1.825. The content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), are the same and do not include new matter. Also enclosed is a copy of the Notice to Comply with Requirements for Patent Application Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures appended to the Office Communication dated April 7, 2003.

The Office Communication mailed April 7, 2003 indicates that the response filed December 18, 2002 was not fully responsive to the Office Communication dated October 22, 2002 due to an unreadable diskette that was melted. It establishes the period for response as set forth in the Office Communication dated October 22, 2002. The Office Communication mailed April 7, 2003 also indicates that the above-referenced application will go abandoned unless the applicant corrects the deficiency and obtains an extension of time under 37 C.F.R. § 1.136.

The response filed December 18, 2002 was fully responsive. The diskette submitted on December 18, 2002 was likely melted upon arrival to the Patent Office and due to Patent Office practice of irradiating all incoming mail to the Washington DC 20231 address.

In addition, the Patent Office did not notify the undersigned attorney until one month before the end of the six month statutory period. Thus, the present submission requires a petition for an extension of time of five months and fee as set forth in 37 C.F.R. § 1.17(a)(5), in an amount of \$985.00. Applicants believe that there is an error in designating the time period for a response to run from the date of the Office Communication mailed October 22, 2002.

However, in an abundance of caution, the applicants submit herewith a petition for an extension of time of five months. The response filed December 18, 2002 was accompanied by a petition for a one month extension of time and the fee of \$55 as set forth in 37 C.F.R. § 1.17(a)(1). Thus, the amount due is \$930.00, the difference between the fee required for a five month extension of time (\$985.00) and a one month extension of time (\$55.00). The Commissioner is authorized to charge this fee to Deposit Account No. 02-4377.


Should any additional fee be required or overpayment made in connection with this submission, they may be charged to Deposit Account No. 02-4377. Two copies of this sheet are enclosed.

Respectfully submitted,

*Carmella L. Stephens*  
Rochelle K. Seide  
Patent Office Reg. No. 32,300

Carmella L. Stephens  
Patent Office Reg. No. 41,328

BAKER BOTT, L.L.P.  
30 Rockefeller Plaza  
45th Floor  
New York, NY 10112  
(212) 408-2500  
*Attorneys for Applicants*

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**